Quantcast

Latest Channelopathy Stories

2008-10-13 09:00:09

Kamada, a biopharmaceutical company, has reported positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin delivered via an investigational eFlow Nebulizer System, in the treatment of cystic fibrosis. The results demonstrate the product has an excellent safety profile and shows promising signs of efficacy, as indicated by a reduction in lung inflammation, the company said. The Phase II trial was a double-blind, placebo-controlled study, performed at the Cystic Fibrosis...

2008-10-01 09:00:09

REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it is seeking a strategic partner to assist in the development of RGN-457 for the treatment of cystic fibrosis (CF). RGN-457 is based on thymosin beta 4 (TB4) peptide formulated as an inhaled therapeutic agent to address this patient population. CF is a life-threatening, hereditary disease that impairs the patient's ability to breathe due to the accumulation of thick and sticky mucus secretions in the airways...

91bc01ae73692d33d495e8e502b41be71
2008-09-26 13:00:00

Scientists hope that a new development, which allows them to create pigs that develop cystic fibrosis in the same way the people do, will give them new insight into fighting the disease. Scientists at the University of Iowa and the University of Missouri have created genetically engineered piglets with the same mutation that causes cystic fibrosis in humans, they report in the journal Science. Up to this point, scientists have been unable to find any hints that may lead to a possible cure,...

2008-09-03 09:00:46

WARRINGTON, Pa., Sept. 3, 2008 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announces that its proprietary, aerosolized KL-4 surfactant has been selected for a Phase 2a clinical trial in patients with Cystic Fibrosis (CF). The trial is being conducted as an investigator-initiated study under the direction of Dr. Scott H. Donaldson at The University of North Carolina and is funded primarily through a grant provided by the Cystic Fibrosis Foundation. The trial is designed as...

2008-09-03 09:00:46

LINCOLN, R.I., Sept. 3 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations for NT-501 for the treatment of visual loss in two indications -- retinitis pigmentosa (RP) and the dry form of age-related macular degeneration (dry AMD). NT-501 is an intraocular, cell containing...

2008-08-30 09:00:20

What was your first experience of cystic fibrosis? I have two grandsons, now in their twenties, who were diagnosed at birth. It's a shock when you hear that news and you don't really know anything about the disease. When you are told, point-blank, they may not live beyond their teenage years, it's frightening. From the day it's diagnosed, you know you're living with a timebomb. What do you now know about the disease? It's a genetic condition which affects internal organs, especially the...

2008-08-22 09:01:11

Kamada has completed a Phase II study with aerosolized alpha-1 antitrypsin, delivered via an optimized eFlow platform nebulizer from PARI Pharma, in cystic fibrosis. The trial aimed at validating the safety of the product in cystic fibrosis patients and to assess its potential influence on lung inflammation. Preliminary results indicate that the product has an excellent safety profile; final data should be available by year-end 2008, said Kamada. The trial, which was a double-blind,...

2008-08-19 06:00:16

Research and Markets (http://www.researchandmarkets.com/research/8e04b4/cystic_fibrosis_w) has announced the addition of Decision Resources, Inc.'s new report "Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies?" to their offering. The cystic fibrosis (CF) market is poised for significant change. The next generation of CF treatments all target the central mechanism responsible for organ damage in CF. These agents, as one thought leader states, "represent the closest we have...

2008-07-14 09:00:14

WALTHAM, Mass., July 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that in 2007, the United States market for the treatment of pulmonary symptoms of cystic fibrosis reached $397 million, reflecting primarily sales of Genentech/Roche's Pulmozyme and Novartis's antibiotic Tobi. Sales of these agents have helped the market grow at more than 15 percent annually since 2000. That growth however,...

2008-07-09 12:00:49

HUNTINGTON BEACH, Calif., July 9 /PRNewswire-USNewswire/ -- Amazingly, surfers have unknowingly held a key to prolonging the lifespan and quality of life for people with cystic fibrosis (CF), a fatal genetic disease that causes the body to produce thick, sticky mucus, which clogs the lungs and leads to life-threatening lung infections. Several years ago, doctors in Australia noticed young surfers with cystic fibrosis had significantly healthier lungs. The doctors determined that inhaling...


Latest Channelopathy Reference Libraries

Cystic Fibrosis
2013-07-19 15:03:45

Cystic fibrosis, also called mucoviscidosis, is an autosomal recessive genetic disorder of the viscous secretions in the body. In turn, it effects the lungs, pancreas, liver, and intestines, as well as all other exocrine glands in the body. The most common genetic mutation that causes CF is a deletion of three nucleotides that results in a loss of phenylalanine, an amino acid at the 508th position on the protein. It should be noted, however, that there are over a thousand other mutations that...

More Articles (1 articles) »
Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related